ONCBeOne MedicinesRunning, no new patients
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Relapsed/Refractory Follicular Lymphoma · Marginal Zone Lymphoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 799 (final count)
- Started
- Mar 10, 2022
- Main results expected
- Jul 2028
- Fully finished
- Jun 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)
Measured over: Approximately 78 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05100862 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC